Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026

Bulletin Express07-15

Ascletis Pharma Inc. (Ascletis) has selected a fixed-dose combination (FDC) of two in-house oral small-molecule agonists—ASC48 (GIPR) and ASC30 (GLP-1R)—for clinical development as a once-daily treatment for obesity.

ASC48 demonstrated an EC50 of 1 pM in the human GIPR cAMP activation assay, showing higher potency than tirzepatide’s 3 pM. The compound is selective for GIPR, with no observed activity on GLP-1R or GCGR, and exhibited favorable oral bioavailability and a long half-life in both rodent and non-human primate (NHP) studies.

In an eight-day, head-to-head NHP study, the ASC30_48 FDC reduced body weight by 10.5%, versus 6.9% for ASC30 monotherapy and 1.7% for ASC48 monotherapy. The FDC’s relative body-weight reduction was 52% greater than ASC30 alone and 518% greater than ASC48 alone.

Positioned as an oral analogue to tirzepatide—which is administered weekly by injection and projected to exceed USD 30 billion in 2025 sales—the once-daily ASC30_48 tablet targets both GLP-1R and GIPR receptors in a single pill. Ascletis expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the fourth quarter of 2026.

The company emphasized that the development, manufacturing, and commercialization of ASC30, ASC48, and their combination remain subject to successful clinical progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110251188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110251188","market":"us","top_or_hot":-1,"title":"Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (Ascletis) has selected a fixed-dose combination (FDC) of two in-house oral small-molecule agonists—ASC48 (GIPR) and ASC30 (GLP-1R)—for clinical development as a once-daily treatment for obesity.</p>\n<p>ASC48 demonstrated an EC50 of 1 pM in the human GIPR cAMP activation assay, showing higher potency than tirzepatide’s 3 pM. The compound is selective for GIPR, with no observed activity on GLP-1R or GCGR, and exhibited favorable oral bioavailability and a long half-life in both rodent and non-human primate (NHP) studies.</p>\n<p>In an eight-day, head-to-head NHP study, the ASC30_48 FDC reduced body weight by 10.5%, versus 6.9% for ASC30 monotherapy and 1.7% for ASC48 monotherapy. The FDC’s relative body-weight reduction was 52% greater than ASC30 alone and 518% greater than ASC48 alone.</p>\n<p>Positioned as an oral analogue to tirzepatide—which is administered weekly by injection and projected to exceed USD 30 billion in 2025 sales—the once-daily ASC30_48 tablet targets both GLP-1R and GIPR receptors in a single pill. Ascletis expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the fourth quarter of 2026.</p>\n<p>The company emphasized that the development, manufacturing, and commercialization of ASC30, ASC48, and their combination remain subject to successful clinical progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-15 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. (Ascletis) has selected a fixed-dose combination (FDC) of two in-house oral small-molecule agonists—ASC48 (GIPR) and ASC30 (GLP-1R)—for clinical development as a once-daily treatment for obesity.</p>\n<p>ASC48 demonstrated an EC50 of 1 pM in the human GIPR cAMP activation assay, showing higher potency than tirzepatide’s 3 pM. The compound is selective for GIPR, with no observed activity on GLP-1R or GCGR, and exhibited favorable oral bioavailability and a long half-life in both rodent and non-human primate (NHP) studies.</p>\n<p>In an eight-day, head-to-head NHP study, the ASC30_48 FDC reduced body weight by 10.5%, versus 6.9% for ASC30 monotherapy and 1.7% for ASC48 monotherapy. The FDC’s relative body-weight reduction was 52% greater than ASC30 alone and 518% greater than ASC48 alone.</p>\n<p>Positioned as an oral analogue to tirzepatide—which is administered weekly by injection and projected to exceed USD 30 billion in 2025 sales—the once-daily ASC30_48 tablet targets both GLP-1R and GIPR receptors in a single pill. Ascletis expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the fourth quarter of 2026.</p>\n<p>The company emphasized that the development, manufacturing, and commercialization of ASC30, ASC48, and their combination remain subject to successful clinical progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1110251188","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110251188","pubTimestamp":1784109876,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (Ascletis) has selected a fixed-dose combination (FDC) of two in-house oral small-molecule agonists—ASC48 (GIPR) and ASC30 (GLP-1R)—for clinical development as a once-daily...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼推进首创口服GLP-1R/GIPR组合；计划于 2026 年第四季度提交 IND","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (Ascletis) has selected a fixed-dose combination (FDC) of two in-house oral small-molecule agonists—ASC48 (GIPR) and ASC30 (GLP-1R)—for clinical development as a once-daily treatment for obesity.\nASC48 demonstrated an EC50 of 1 pM in the human GIPR cAMP activation assay, showing higher potency than tirzepatide’s 3 pM. The compound is selective for GIPR, with no observed activity on GLP-1R or GCGR, and exhibited favorable oral bioavailability and a long half-life in both rodent and non-human primate (NHP) studies.\nIn an eight-day, head-to-head NHP study, the ASC30_48 FDC reduced body weight by 10.5%, versus 6.9% for ASC30 monotherapy and 1.7% for ASC48 monotherapy. The FDC’s relative body-weight reduction was 52% greater than ASC30 alone and 518% greater than ASC48 alone.\nPositioned as an oral analogue to tirzepatide—which is administered weekly by injection and projected to exceed USD 30 billion in 2025 sales—the once-daily ASC30_48 tablet targets both GLP-1R and GIPR receptors in a single pill. Ascletis expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the fourth quarter of 2026.\nThe company emphasized that the development, manufacturing, and commercialization of ASC30, ASC48, and their combination remain subject to successful clinical progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110251188","isCrawlerRequest":true}